Key Highlights
● Second-quarter revenue rose 38 per cent year over year to $753.2 million.
● Rest of World revenue surged after the Eucalyptus acquisition closed in June.
● The company swung to a net loss of $86.3 million amid shrinking margins.
● Full-year 2026 revenue guidance was raised to $3.1 billion to $3.3 billion.
Hims & Hers Health (NYSE:HIMS) operates a telehealth platform selling personalised treatments and wellness products, including weight management, dermatology, sexual health and mental health. Its Class A common stock trades on the New York Stock Exchange under HIMS. The company does not pay a dividend, so no yield applies. The business has recently changed shape through its international expansion and a revised approach to GLP-1 weight-loss treatments. Its growth over the past several years has been rapid, and the latest results show how acquisitions and new product categories are reshaping both revenue mix and costs.
Second-quarter 2026 results
On 10 August 2026 the company reported second-quarter revenue of $753.2 million, up 38 per cent from $544.8 million. United States revenue was $621.8 million, up 16 per cent, while Rest of World revenue reached $131.4 million compared with $7.5 million, reflecting the Eucalyptus acquisition that closed in June. Subscribers ended the period at 2.89 million, up 19 per cent, and monthly revenue per average subscriber was $92, up 21 per cent. Profitability weakened. The company recorded a net loss of $86.3 million against net income of $42.5 million a year earlier, and adjusted EBITDA fell to $60.3 million, an 8 per cent margin, from $82.2 million at 15 per cent. Gross margin was 64 per cent compared with 76 per cent, a decline that coincides with the shift towards branded GLP-1 access and acquired businesses,. First-half revenue was $1.36 billion, up 20 per cent, and first-half net loss was $178.4 million, so the second quarter was not an isolated item. Restructuring charges were $4.6 million in the quarter.
Cash, debt and obligations
Operating cash flow was negative $35.9 million in the quarter and free cash flow negative $68.2 million, though first-half operating cash flow was positive at $53.4 million. Cash and equivalents stood at $609.8 million, with a further $231.2 million of short-term investments. Convertible senior notes had a net carrying value of $1.37 billion, up from $972.6 million at the end of 2025, after $390.4 million of net issuance proceeds in the half. Acquisition payments totalled $318.1 million for the half, and deferred acquisition payables were $537.4 million current and $165.6 million long term. Legal contingencies charged to the quarter were $47.5 million. These obligations are material relative to cash balances and are a central consideration for the balance sheet. Free cash flow therefore turned negative in the quarter even as the balance sheet gained liquidity from financing,.
Scale Is Outrunning Profitability
Hims & Hers enters the back half of 2026 with subscriber growth, international expansion and raised full-year guidance working in its favor, but the quarter's swing to a net loss and the compression in gross and EBITDA margins show the costs of that expansion are rising just as fast. Convertible debt and deferred acquisition payables add leverage to a balance sheet that still carries a sizable cash position, leaving the path from rapid revenue growth to durable profitability as the key question heading into the November 9 report.






Please wait processing your request...